NeuroSense Therapeutics Ltd
Research NeuroSense Therapeutics Ltd (NRSN) on Bullrun: market cap USD 12.76M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNRSN
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 12.76M
- Financial periodFY2025
- Net income-USD 11.13M
- Free cash flow-USD 7.68M
Valuation Snapshot
latest market cap is USD 12.76M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -USD 11.13M | -USD 7.68M | n/a | -0.44 | USD 166.00K | USD 170.00K | -USD 1.56M |
| FY2024 | USD 0 | -USD 10.21M | -USD 10.14M | n/a | -0.54 | USD 3.38M | USD 73.00K | USD 2.58M |
| FY2023 | n/a | -USD 10.11M | -USD 8.38M | n/a | -0.74 | USD 2.64M | USD 142.00K | -USD 1.76M |
| FY2022 | n/a | -USD 10.49M | -USD 7.69M | n/a | -0.91 | USD 3.54M | USD 190.00K | USD 5.84M |
| FY2021 | n/a | -USD 3.22M | -USD 1.56M | n/a | -0.52 | USD 11.06M | n/a | USD 10.83M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 12.76M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 25.07M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 27.87M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 10.80M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 14.37M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 26.92M | n/a | n/a | n/a |
About NeuroSense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NeuroSense Therapeutics Ltd's market cap?
NeuroSense Therapeutics Ltd's market capitalization is USD 12.76M.
What does NeuroSense Therapeutics Ltd do?
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.